{"title":"[Selection of blood products to reduce immunization before HLA-mismatched allogeneic transplantation (SFGM-TC)].","authors":"Roberto Crocchiolo, Maude Avias, Caroline Baud, Laure Croisille, Marion Francois, Nicolas Guillaume, Elham Harfouch, Thibault Pajot, Pascal Pedini, Elodie Wojciechowski, Leonardo Magro, Valérie Dubois","doi":"10.1016/j.bulcan.2025.03.016","DOIUrl":null,"url":null,"abstract":"<p><p>The increase of HLA-mismatched allogeneic stem cell transplantation, due to the use of post-transplant high-dose cyclophosphamide, has highlighted the detrimental impact of anti-HLA antibodies in the recipient, especially those directed against the donor (donor specific antibodies [DSA]), on transplant success. Blood products transfusions, in particular platelets, are a source of immunisation against donor HLA antigens and patients candidates to HLA-mismatched transplantation are at risk of developing DSA because of the elevated transfusion need. This Atelier gathers Immunogenetics and Transfusion Medicine experts to deal with the prevention of anti-HLA immunisation of patients waiting to HLA-mismatched transplantation, through the appropriate selection of blood products thus avoiding the appearance of DSA and optimising the engraftment rate.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin du cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bulcan.2025.03.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The increase of HLA-mismatched allogeneic stem cell transplantation, due to the use of post-transplant high-dose cyclophosphamide, has highlighted the detrimental impact of anti-HLA antibodies in the recipient, especially those directed against the donor (donor specific antibodies [DSA]), on transplant success. Blood products transfusions, in particular platelets, are a source of immunisation against donor HLA antigens and patients candidates to HLA-mismatched transplantation are at risk of developing DSA because of the elevated transfusion need. This Atelier gathers Immunogenetics and Transfusion Medicine experts to deal with the prevention of anti-HLA immunisation of patients waiting to HLA-mismatched transplantation, through the appropriate selection of blood products thus avoiding the appearance of DSA and optimising the engraftment rate.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
